WO2013002717A1 - Method of determining active concentration by calibration-free analysis - Google Patents

Method of determining active concentration by calibration-free analysis Download PDF

Info

Publication number
WO2013002717A1
WO2013002717A1 PCT/SE2012/050717 SE2012050717W WO2013002717A1 WO 2013002717 A1 WO2013002717 A1 WO 2013002717A1 SE 2012050717 W SE2012050717 W SE 2012050717W WO 2013002717 A1 WO2013002717 A1 WO 2013002717A1
Authority
WO
WIPO (PCT)
Prior art keywords
analyte
concentration
ligand
sample
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/SE2012/050717
Other languages
French (fr)
Inventor
Robert Karlsson
Håkan ROOS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Global Life Sciences Solutions USA LLC
Original Assignee
GE Healthcare Bio Sciences Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GE Healthcare Bio Sciences Corp filed Critical GE Healthcare Bio Sciences Corp
Priority to CN201280032274.8A priority Critical patent/CN103620410B/en
Priority to US14/130,009 priority patent/US20140141529A1/en
Priority to JP2014518495A priority patent/JP5855246B2/en
Priority to EP12805115.8A priority patent/EP2726876B1/en
Publication of WO2013002717A1 publication Critical patent/WO2013002717A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366Apparatus specially adapted for solid-phase testing
    • G01N33/54373Apparatus specially adapted for solid-phase testing involving physiochemical end-point determination, e.g. wave-guides, FETS, gratings
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/55Specular reflectivity
    • G01N21/552Attenuated total reflection
    • G01N21/553Attenuated total reflection and using surface plasmons
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/75Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
    • G01N21/77Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator

Definitions

  • the present invention relates to the determination of the concentration of a bioanalyte, such as a protein, and more particularly to the determination of the active concentration of the bioanalyte.
  • the active concentration of a biomolecule may conveniently be measured by biosensor technology, wherein a sample containing the biomolecule is contacted with a sensor surface with a specific ligand immobilized thereon, and the association/ dissociation process at the surface is monitored. In this case it is the choice of ligand that defines the activity being measured.
  • active concentration is measured using a calibration curve.
  • the analyte concentration can be determined without reference to a calibration standard, using the relationship between the diffusion properties of the analyte and the analyte concentration.
  • the analyte concentration can be calculated.
  • CFCA Calibration-Free Concentration Analysis
  • the present invention therefore provides a method of determining active concentration of an analyte in a liquid sample, comprising the steps of:
  • step (c) fitting the initial binding rate data obtained in step (b) to a kinetic interaction model that includes a term for mass transport to obtain the active analyte concentration
  • steps (a) and (b) are performed at a plurality of different dilutions of the liquid sample
  • step (c) wherein in step (c) at least several of the plurality of dilutions of the liquid sample are in included in a global fit of initial binding rate data to the kinetic interaction model.
  • the method is performed at two substantially different flow rates.
  • the different flow rates are obtained by varying the flow rate during a single contacting (e.g. injection) cycle.
  • At least three, and preferably at least five different sample dilutions are used.
  • the method of the invention may conveniently be implemented by software run on an electrical data processing device, such as a computer.
  • Such software may be provided to the computer on any suitable computer-readable medium, including a record medium, a read-only memory, or an electrical or optical signal which may be conveyed via electrical or optical cable or by radio or other means.
  • Another aspect of the invention therefore relates to a computer program product comprising instructions for causing a computer to perform the method steps of the mentioned method aspect above.
  • Figure 1 is a plot of fitted binding versus time data for two different flow rates in conventional CFCA.
  • Figure 2 is a plot of globally fitted binding versus time data at several
  • the present invention relates to the determination of the active concentration of an analyte, typically a bioanalyte, in a fluid sample.
  • the method comprises performing calibration-free concentration analysis under at least partial transport limitation on several dilutions of a liquid sample containing the analyte whose concentration is to be determined, and including several or all dilutions in a global fit of concentration data, the same fitting criteria being applied to several dilutions.
  • an interaction analysis sensor is used in the active concentration determination, typically a biosensor.
  • a biosensor is typically based on label-free techniques, detecting a change in a property of a sensor surface, such as mass, refractive index or thickness of the immobilized layer.
  • Typical biosensors for the purposes of the present invention are based on mass detection at the sensor surface and include especially optical methods and piezoelectric or acoustic wave methods.
  • Representative sensors based on optical detection methods include those that detect mass surface concentration, such as sensors based on reflection-optical methods, including e.g. evanescent wave-based sensors including surface plasm on resonance (SPR) sensors; frustrated total reflection (FTR) sensors, and waveguide sensors, including e.g. reflective interference spectroscopy (RIfS) sensors.
  • Piezoelectric and acoustic wave sensors include surface acoustic wave (SAW) and quartz crystal microbalance (QCM) sensors.
  • Biosensor systems based on SPR and other detection techniques are commercially available.
  • Exemplary such SPR-biosensors include the flow-through cell-based Biacore ® systems (GE Healthcare, Uppsala, Sweden) and ProteOnTM XPR system (Bio-Rad Laboratories, Hercules, CA, USA) which use surface plasmon resonance for detecting interactions between molecules in a sample and molecular structures immobilized on a sensing surface. As sample is passed over the sensor surface, the progress of binding directly reflects the rate at which the interaction occurs.
  • Injection of sample is usually followed by a buffer flow during which the detector response reflects the rate of dissociation of the complex on the surface.
  • a typical output from the system is a graph or curve describing the progress of the molecular interaction with time, including an association phase part and a dissociation phase part.
  • This binding curve which is usually displayed on a computer screen, is often referred to as a "sensorgram”.
  • Biacore ® systems it is thus possible to determine in real time without the use of labeling, and often without purification of the substances involved, not only the presence and concentration of a particular molecule, or analyte, in a sample, but also additional interaction parameters, including kinetic rate constants for association (binding) and dissociation in the molecular interaction as well as the affinity for the surface interaction.
  • the Biacore ® systems as well as analogous sensor systems, measure the active analyte concentration as distinct from the total concentration of the analyte, the choice of ligand on the sensor surface defining the kind of activity being measured.
  • an analyte When an analyte is injected into a laminar flow system, e.g. of the Biacore ® system type, in such a way that the analyte contacts a sensor surface, it will give rise to a binding event.
  • the rate of the analyte /ligand interaction will be determined by the interaction kinetics and by the transport efficiency of the flow system.
  • k a and kd are the rate constants for the association and dissociation, respectively.
  • the association rate is given by k a [A][B] and the dissociation rate is given by kd[AB].
  • the net rate of binding i.e. the change in surface concentration of formed complex B is therefore at
  • R is the response in response units
  • C is the concentration of analyte in the sample
  • R ma x is the response obtained if analyte (A) had bound to all ligand (B) on the surface, i.e. the maximum analyte binding capacity.
  • the kinetic rate constants k a and kd are typically calculated by fitting response data for, preferably, a number of different concentrations of analyte and, preferably, also at least one other ligand density at the sensor surface to equation (4) above, or to the integrated form thereof:
  • binding model is fitted simultaneously to multiple binding curves obtained with different analyte concentrations C (and / or with different levels of surface derivatization R ma x) .
  • This is referred to as "global fitting", and based on the sensorgram data such global fitting establishes whether a single global k a or kd will provide a good fit to all the data.
  • the observed rate of binding at any time will be determined by the relative magnitudes of the net biochemical interaction rate and the rate of mass transport. If interaction is much faster than transport, the observed binding will be limited entirely by the transport processes. This is also the case when the analyte does not diffuse fast enough from the surface during dissociation, leading to re-binding. Conversely, if transport is fast and interaction is slow, the observed binding will represent the interaction kinetics alone. When the rates of the two processes are of similar orders of magnitude, the binding will be determined by a combination of the two rate characteristics.
  • Asurface is the analyte concentration at the sensor surface
  • Abuik is the analyte concentration in the bulk solution
  • k m is the mass transport coefficient
  • the differential equation describing the binding interaction will therefore include a term for mass transfer of analyte to the surface corresponding to equation (8) above.
  • a"two- compartment" model consisting of a set of coupled ordinary differential equations and described in, for example, Myszka, D. G. et al. (1998) Biophys. J. 75,583-594 is considered to give a reasonable description of the binding kinetics when the data are influenced by mass transport.
  • the flow cell is assumed to be divided into two compartments, one in which the concentration of analyte is constant, and a second near the sensor surface where the analyte concentration depends on the mass transport rate, the surface density of ligand, and the reaction rate constants.
  • the mass transport coefficient k m can be calculated, and fitting of response data to equations (9) and (10) will give the kinetic rate constants k a and kd.
  • D is the diffusion coefficient (m 2 /s) of the analyte
  • F is the volumetric flow rate of liquid through the flow cell (m 3 /s)
  • h, w and 1 are the flow cell
  • the diffusion coefficient D is a function of the size and shape of the molecule and the frictional resistance offered by the viscosity of the solvent in question.
  • the diffusion coefficient is inversely proportional to the radius and thus proportional to the cube root of the molecular weight.
  • the diffusion coefficient is relatively insensitive to the molecular weight.
  • the diffusion coefficient may be estimated from the molecular and the shape factor, or frictional rate, according to the equation
  • D is the diffusion coefficient (m 2 /s)
  • M is the molecular weight (daltons)
  • f is the frictional ratio
  • ⁇ ⁇ ⁇ is the viscosity of the solvent relative to water at 20° C.
  • k m the mass transport coefficient k m can thus be calculated.
  • a Biacore-specific mass transfer constant kt may be obtained by adjusting for the molecular weight of the analyte and conversion from measured response (in RU) to concentration units:
  • the mass transport coefficient is calculated from the diffusion coefficient, and then converted to the mass transport constant kt which is used in fitting the experimental data to the diffusion-controlled interaction model whereby the analyte concentration of the sample can be obtained.
  • CFCA calibration-free concentration assays
  • analyte e.g. a protein
  • CFCA calibration-free concentration assays
  • a liquid sample containing the analyte e.g. a protein
  • the analyte concentration C is then evaluated, typically by dedicated software, by fitting the binding data to a model with a global variable for the analyte concentration. That is, setting the analyte concentration as a parameter to fit and k m as a known constant together with the molecular weight Mw, so that the model is constrained to find a single concentration value that best fits all binding curves simultaneously.
  • the current implementation of the technology in Biacore ® systems involves two binding experiments where analyte binds to immobilized ligand; one experiment at a low flow rate (often 5 or 10 ⁇ /min) and one experiment at a high flow rate (often 100 ⁇ /min).
  • responses are checked for transport (diffusion) limited behavior and the response is fitted to a kinetic model where the transport coefficient is constant and the concentration of the analyte is fitted.
  • binding rates should be measured shortly after start of the sample injection, since the rates approach zero as the binding approaches a steady state.
  • Calibration-free assays are usually set up a direct binding format in order to obtain the high binding capacities that are usually required.
  • CFCA experiments several dilutions of the sample are analysed and evaluated separately.
  • a more robust analysis and one which has an extended dynamic range is obtained by including several (e.g. at least three) or all dilutions in a global fit of concentration data, so that the same fitting criteria are applied to several dilutions of the sample. This will also facilitate sensitivity analysis of the results as it becomes possible to determine whether other concentration values can be used to obtain identical or similar quality of global analysis.
  • the scripting language used in the dedicated Biaevaluation software may, for example, be as follows: The total response comes from complex formation and from refractive index change AB+$1*RI.
  • $ 1 (sign(t-ton 1 ) -sign(t-toff 1 )) / 2 ;
  • S2 describes the transport of analyte to the sensor surface, kt corresponds to the transport coefficient at one ⁇ /min.
  • Fl is the flow rate.
  • Cone is the stock
  • Dil is the dilution factor that gives the concentration in the actual sample.
  • A is the cone of analyte at the sensor surface.
  • A describes how the the analyte concentration varies over time.
  • the starting value is zero.
  • the starting value is Rmax.
  • AB is how the complex is formed.
  • ka, kd, Rmax are fitted globally (Rmax can be locally/ globally fitted to subgroups when several ligand densities are used);
  • $ 1 (sign(t-ton 1 ) -sign(t-tonoff)) / 2 ;
  • sample injections may be made for each different flow rate
  • the need to inject samples in two or more cycles may be overcome by the "single cycle" approach described above, where the flow rate varies during one sample injection.
  • the sample may be injected at 10 ⁇ /min, and after 5-20 seconds the flow rate is increased to 100 ⁇ /min. In the data analysis, this is handled by input of actual flow rates in the evaluation algorithms used.
  • the method of the invention may, optionally, be combined with a newly developed calibration-free concentration analysis method where sensor surfaces or surface areas with varying ligand density (i.e. an array of different ligand densities) are used and a fitting algorithm for determining the maximum initial binding rate and thereby the active concentration is provided.
  • sensor surfaces or surface areas with varying ligand density i.e. an array of different ligand densities
  • R is the detector response
  • k m is the mass transport coefficient
  • C is the analyte concentration of the sample. That is, the response increase dR/dt, or binding rate, at the sensor surface is proportional to the mass transport coefficient and the active concentration of the analyte. From equation (14) it is seen that if the (initial) binding rate dR/dt at total transport limitation and k m are known, the analyte concentration C may be calculated by dividing dR/dt by k m .
  • initial binding rates are measured at a number of (preferably at least four) different ligand density levels, i.e. immobilization levels. For each immobilization level, the response is recorded using at least one fixed flow rate.
  • the initial binding rate is plotted versus the immobilization level, or maximal binding capacity R ma x, and the binding rate where dR/dt has reached its maximum is determined by extrapolation of the data, typically using an algorithm capable thereof.
  • This maximum binding rate corresponds to the binding rate at mass transport limitation, meaning that equation (14) above applies, and the active concentration C can therefore be calculated by dividing dR/dt by k m .
  • the contacting of the sample with surfaces or surface areas with different ligand densities may be performed in an analytical instrument having a single sensor surface by sequential sample injections and varying the ligand density between injections.
  • the method is performed with a multi-flow channel instrument, such as the BiacoreTM T100, T200 or 4000 (GE Healthcare, Uppsala, Sweden) or ProteOnTM XPR system (Bio-Rad Laboratories, Hercules, CA, USA), preferably by parallel sample injections.
  • a multi-flow channel instrument such as the BiacoreTM T100, T200 or 4000 (GE Healthcare, Uppsala, Sweden) or ProteOnTM XPR system (Bio-Rad Laboratories, Hercules, CA, USA), preferably by parallel sample injections.
  • (initial) binding rate data are collected at different immobilization levels and at different flow rates at partial or complete transport limitation for a number of different sample dilutions.
  • binding rate data i.e. either by (i) analysis under partial transport limitation with global fitting of data for several dilutions of a sample; or (ii) extrapolation to complete transport limitation; or (iii) a combination of (i) and (ii).
  • a procedure for determining active concentration by the method of the present invention using, for example, a modified Biacore ® T200 system may be performed as follows.
  • the experiments described here demonstrate antibody binding to an immobilized protein A derivative capable of binding antibody.
  • the conventional CFCA analysis is illustrated in Fig. 1.
  • the analyte was injected in separate cycles at varying flow rates. In this case the analyte was diluted 400 times relative to its stock concentration. CFCA analysis gives the local antibody concentration as 19.1 nM and thus the stock solution is 7.6 ⁇ .
  • This graph illustrates the global fit of antibody dilutions 1:400, 1 : 1200, 1 :3600 and 1: 10800. Each dilution is injected at two flow rates and the globally determined concentration for the stock solution is 7.6 ⁇ . This immediately demonstrates that the concentration analysis is not dilution dependent and simplifies the analysis.

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plasma & Fusion (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

A method of determining active concentration of an analyte in a liquid sample, comprises the steps of: (a)contacting a laminar flow of the sample with a solid phase surface or surface area supporting a ligand capable of specifically binding the analyte at at least two different flow rates and under partially or completely mass transport limited conditions; (b)determining the initial binding rate dR/dt of analyte to the ligand at the ligand-supporting surface or surface area, and (c) fitting the initial binding rate data obtained in step (b) to a kinetic interaction model that includes a term for mass transport to obtain the active analyte concentration, wherein steps (a) and (b) are performed at a plurality of different dilutions of the liquid sample, and wherein in step (c) at least several of the plurality of dilutions of the liquid sample are in included in a global fit of initial binding rate data to the kinetic interaction model.

Description

METHOD OF DETERMINING ACTIVE CONCENTRATION BY CALIBRATION- FREE ANALYSIS
Field of the invention
The present invention relates to the determination of the concentration of a bioanalyte, such as a protein, and more particularly to the determination of the active concentration of the bioanalyte.
Background of the invention
There are numerous ways to determine the concentration of proteins and other biomolecules, the majority of the methods involving comparison of the sample to a standard preparation. In many cases, however, no standard is available or the activity of the standard is uncertain. Many times it is also of importance to know the active concentration of bioanalytes rather than the total concentration which may include functionally inactive molecules. This is, for instance, the case in the development and production of biotherapeutics. However, many established methods for measurement of protein concentration do not distinguish between active and inactive molecules.
Thus, whereas the total concentration of e.g. a protein is typically measured by UV or NIR absorption spectrometry which do not distinguish between active and inactive molecules, the active concentration of a biomolecule may conveniently be measured by biosensor technology, wherein a sample containing the biomolecule is contacted with a sensor surface with a specific ligand immobilized thereon, and the association/ dissociation process at the surface is monitored. In this case it is the choice of ligand that defines the activity being measured.
Conventionally, active concentration is measured using a calibration curve. In a development of the determination of active concentration using biosensor technology, however, the analyte concentration can be determined without reference to a calibration standard, using the relationship between the diffusion properties of the analyte and the analyte concentration. Thus, if the diffusion coefficient of the analyte is known, the analyte concentration can be calculated. This type of concentration measurement, which can be useful when no satisfactory calibrant is available for an analyte under study, is usually referred to as Calibration-Free Concentration Analysis (CFCA), and relies upon measurement of analyte binding at varying flow rates under conditions where the observed rate of binding is partially or completely limited by transport of analyte molecules to the sensor surface, i.e. partially or completely controlled by diffusion.
Using surface plasmon resonance detection, CFCA was first described by Karlsson, R., et al. (1993), J. Immunol. Methods 166(l):75-8, and further by Sigmundsson, K., et al. (2002) Biochemistry 41 (26):8263-76. This methodology has been implemented in the commercial Biacore® systems (marketed by GE Healthcare, Uppsala,
Sweden).
In the Biacore® instruments, samples are injected on a micro-flow system and transported by laminar flow to the sensor surface. Molecules reach the sensor surface from bulk solution by a diffusion controlled transport process. In addition to the concentration of analyte molecules, factors influencing the transport rate include the diffusion coefficient, flow cell dimensions, and flow rate. The balance between the transport rate and the binding rate determines whether the observed binding will be transport limited or reaction limited. For successful CFCA, the observed binding rate must, as mentioned above, be at least partially limited by transport.
It is an object of the present invention to provide an improvement of the above described method for calibration-free concentration analysis under partial or complete transport limitation.
Summary of the invention
The above mentioned object as well as other objects and advantages are obtained by a method for on determination of active concentration based on the method for CFCA as outlined above but where measurements are made at multiple sample dilutions and several (or all) dilutions are included in global fit, the same fitting criteria being applied to several dilutions. This makes the analysis more robust and extends the dynamic range. In one aspect, the present invention therefore provides a method of determining active concentration of an analyte in a liquid sample, comprising the steps of:
(a) contacting a laminar flow of the sample with a solid phase surface or surface area supporting a ligand capable of specifically binding the analyte at a plurality of different flow rates and under partially or completely mass transport limited conditions;
(b) determining the initial binding rate dR/dt of analyte to the ligand at the ligand-supporting surface or surface area, and
(c) fitting the initial binding rate data obtained in step (b) to a kinetic interaction model that includes a term for mass transport to obtain the active analyte concentration,
wherein steps (a) and (b) are performed at a plurality of different dilutions of the liquid sample, and
wherein in step (c) at least several of the plurality of dilutions of the liquid sample are in included in a global fit of initial binding rate data to the kinetic interaction model.
In a preferred embodiment, the method is performed at two substantially different flow rates.
In another preferred embodiment, the different flow rates are obtained by varying the flow rate during a single contacting (e.g. injection) cycle.
In still another preferred embodiment, at least three, and preferably at least five different sample dilutions are used.
In yet another preferred embodiment the method additionally comprises
determining active concentration by contacting a laminar flow of the liquid sample with a plurality of solid phase surfaces or surface areas, each surface or surface area having a different ligand density, determining from the initial binding rates the initial binding rate corresponding to transport-limited interaction at the surfaces or surface areas, and from that binding rate determining the active analyte
concentration. Other preferred embodiments are set forth in the dependent claims. The method of the invention may conveniently be implemented by software run on an electrical data processing device, such as a computer. Such software may be provided to the computer on any suitable computer-readable medium, including a record medium, a read-only memory, or an electrical or optical signal which may be conveyed via electrical or optical cable or by radio or other means.
Another aspect of the invention therefore relates to a computer program product comprising instructions for causing a computer to perform the method steps of the mentioned method aspect above.
A more complete understanding of the present invention, as well as further features and advantages thereof, will be obtained by reference to the following detailed description and the accompanying drawings.
Brief description of the drawings
Figure 1 is a plot of fitted binding versus time data for two different flow rates in conventional CFCA. Figure 2 is a plot of globally fitted binding versus time data at several
concentrations analysed at the same time.
Detailed description of the invention
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by a person skilled in the art related to this invention. Also, the singular forms "a", "an", and "the" are meant to include plural reference unless it is stated otherwise.
As mentioned above, the present invention relates to the determination of the active concentration of an analyte, typically a bioanalyte, in a fluid sample. In brief, the method comprises performing calibration-free concentration analysis under at least partial transport limitation on several dilutions of a liquid sample containing the analyte whose concentration is to be determined, and including several or all dilutions in a global fit of concentration data, the same fitting criteria being applied to several dilutions. Preferably, an interaction analysis sensor is used in the active concentration determination, typically a biosensor. Before describing the present invention in more detail, the concept of biosensors and the detection of interactions kinetics will be briefly described.
A biosensor is typically based on label-free techniques, detecting a change in a property of a sensor surface, such as mass, refractive index or thickness of the immobilized layer. Typical biosensors for the purposes of the present invention are based on mass detection at the sensor surface and include especially optical methods and piezoelectric or acoustic wave methods. Representative sensors based on optical detection methods include those that detect mass surface concentration, such as sensors based on reflection-optical methods, including e.g. evanescent wave-based sensors including surface plasm on resonance (SPR) sensors; frustrated total reflection (FTR) sensors, and waveguide sensors, including e.g. reflective interference spectroscopy (RIfS) sensors. Piezoelectric and acoustic wave sensors include surface acoustic wave (SAW) and quartz crystal microbalance (QCM) sensors.
Biosensor systems based on SPR and other detection techniques are commercially available. Exemplary such SPR-biosensors include the flow-through cell-based Biacore® systems (GE Healthcare, Uppsala, Sweden) and ProteOn™ XPR system (Bio-Rad Laboratories, Hercules, CA, USA) which use surface plasmon resonance for detecting interactions between molecules in a sample and molecular structures immobilized on a sensing surface. As sample is passed over the sensor surface, the progress of binding directly reflects the rate at which the interaction occurs.
Injection of sample is usually followed by a buffer flow during which the detector response reflects the rate of dissociation of the complex on the surface. A typical output from the system is a graph or curve describing the progress of the molecular interaction with time, including an association phase part and a dissociation phase part. This binding curve, which is usually displayed on a computer screen, is often referred to as a "sensorgram". With the Biacore® systems it is thus possible to determine in real time without the use of labeling, and often without purification of the substances involved, not only the presence and concentration of a particular molecule, or analyte, in a sample, but also additional interaction parameters, including kinetic rate constants for association (binding) and dissociation in the molecular interaction as well as the affinity for the surface interaction.
In the following, the present invention will to a large extent be described, for illustration only and no limitation, with reference to SPR sensors of the Biacore® system type.
As mentioned above, the Biacore® systems, as well as analogous sensor systems, measure the active analyte concentration as distinct from the total concentration of the analyte, the choice of ligand on the sensor surface defining the kind of activity being measured.
When an analyte is injected into a laminar flow system, e.g. of the Biacore® system type, in such a way that the analyte contacts a sensor surface, it will give rise to a binding event. The rate of the analyte /ligand interaction will be determined by the interaction kinetics and by the transport efficiency of the flow system.
For a biochemical interaction the rate at which an interaction proceeds is given by the difference between the forward (association) and the reverse (dissociation) processes. For a reversible 1 : 1 interaction between an analyte A and a surface- bound (immobilised) capturing molecule or ligand B which is not diffusion or mass transfer limited ka
A + B * " AB (1)
kd
where ka and kd are the rate constants for the association and dissociation, respectively. The association rate is given by ka[A][B] and the dissociation rate is given by kd[AB]. The net rate of binding (i.e. the change in surface concentration of formed complex B) is therefore at
After a time t, the concentration of unbound ligand B at the surface is [Βτ] - [AB], where [Βτ] is the total, or maximum, concentration of ligand B. Insertion into equation (2) above gives
Figure imgf000008_0001
In terms of detector response units (in Biacore® systems formation of complex is observed as an increase in response, measured in resonance units (RU)), this can be expressed as
— = kaC{Rw - R) - kdR (4) were R is the response in response units, C is the concentration of analyte in the sample, and Rmax is the response obtained if analyte (A) had bound to all ligand (B) on the surface, i.e. the maximum analyte binding capacity.
The kinetic rate constants ka and kd are typically calculated by fitting response data for, preferably, a number of different concentrations of analyte and, preferably, also at least one other ligand density at the sensor surface to equation (4) above, or to the integrated form thereof:
p _ ft-q ^Snax Q -(kaC+kd )t
Software for the analysis of kinetic and affinity data is commercially available.
Thus, for example, evaluation of kinetic and affinity data produced by the Biacore® instruments is usually performed with the dedicated BIAevaluation software (supplied by GE Healthcare, Uppsala, Sweden) using numerical integration to calculate the differential rate equations and non-linear regression to fit the kinetic and affinity parameters by finding values for the variables that give the closest fit, reducing the sum of squared residuals to a minimum. The "residuals" are the difference between the calculated and the experimental curve at each point, squared residuals being used to weight equally deviations above and below the experimental curve. The sum of squared residual is expressed by the equation:
S =∑(r, - rx f (6)
/
where S is the sum of squared residuals, rf is the fitted value at a given point, and rx is the experimental value at the same point. For example, for the molecular interaction described above, such software-assisted data analysis is performed by, after subtracting background noises, making an attempt to fit the above-mentioned simple 1 : 1 binding model as expressed by equations (4) or (5) above to the measurement data.
Usually the binding model is fitted simultaneously to multiple binding curves obtained with different analyte concentrations C (and / or with different levels of surface derivatization Rmax) . This is referred to as "global fitting", and based on the sensorgram data such global fitting establishes whether a single global ka or kd will provide a good fit to all the data.
The above is, however, only valid for a reaction which is not diffusion or mass transfer limited. Thus, for analyte to bind to the sensor surface, the molecule must be transported from the bulk solution to the sensor surface, which is a diffusion limited process. Under conditions of laminar flow, which apply in the Biacore® and analogous biosensor systems, the transport rate is proportional to the concentration of analyte in the bulk solution.
In a given analysis situation, the observed rate of binding at any time will be determined by the relative magnitudes of the net biochemical interaction rate and the rate of mass transport. If interaction is much faster than transport, the observed binding will be limited entirely by the transport processes. This is also the case when the analyte does not diffuse fast enough from the surface during dissociation, leading to re-binding. Conversely, if transport is fast and interaction is slow, the observed binding will represent the interaction kinetics alone. When the rates of the two processes are of similar orders of magnitude, the binding will be determined by a combination of the two rate characteristics.
The overall interaction process can be represented by the scheme
Abuik <→ Asurface + B <→ AB (7)
The rate of mass transport from bulk solution to the surface is given by
^ -A surface ] 7 r . η
=km iAbulk (8) where Asurface is the analyte concentration at the sensor surface, Abuik is the analyte concentration in the bulk solution and km is the mass transport coefficient.
The differential equation describing the binding interaction will therefore include a term for mass transfer of analyte to the surface corresponding to equation (8) above. For a flow cell, a"two- compartment" model consisting of a set of coupled ordinary differential equations and described in, for example, Myszka, D. G. et al. (1998) Biophys. J. 75,583-594 is considered to give a reasonable description of the binding kinetics when the data are influenced by mass transport. In this model, the flow cell is assumed to be divided into two compartments, one in which the concentration of analyte is constant, and a second near the sensor surface where the analyte concentration depends on the mass transport rate, the surface density of ligand, and the reaction rate constants.
For the interaction exemplified above of a monovalent analyte A reacting with an immobilised monovalent ligand B, this model may be represented by the following two differential equations replacing equation (3) above - d^ -- (- A BT - AB) + kdAB + km (Ablllk - A) (9) ^- = K ^ BT - AE) - kdAB (10) where km is the mass transport coefficient (describing diffusive movement of analyte between the compartments), Βτ is the total ligand concentration, Asurface is the concentration of free analyte at the sensor surface, Abuik is the injection (i. e. initial) analyte concentration, AB is the concentration of complex AB (= surface density of bound analyte), and ka and kd are the association and dissociation rate constants, respectively.
As will be described in more detail below, the mass transport coefficient km can be calculated, and fitting of response data to equations (9) and (10) will give the kinetic rate constants ka and kd.
The kinetic characterizations outlined above have traditionally been performed using either the well-established method where each sample concentration is run in a separate cycle, and analyte is removed by regeneration of the surface between each cycle. In a more recently developed approach, however, referred to as "single cycle analysis", the analyte is injected with increasing (or otherwise varied) concentrations in a single cycle, the surface not being regenerated between injections. For a more detailed description of such single cycle analysis it may be referred to Karlsson, R., et al. (2006) Anal. Biochem. 349: 136- 147 (the disclosure of which is incorporated by reference herein).
For the above-mentioned mass transport coefficient km, the following equation applies
Figure imgf000011_0001
where D is the diffusion coefficient (m2/s) of the analyte, F is the volumetric flow rate of liquid through the flow cell (m3/s), and h, w and 1 are the flow cell
dimensions (height, width, length (m)). The diffusion coefficient D is a function of the size and shape of the molecule and the frictional resistance offered by the viscosity of the solvent in question. For spherical molecules, the diffusion coefficient is inversely proportional to the radius and thus proportional to the cube root of the molecular weight. For very large solute molecules, such as proteins, however, the diffusion coefficient is relatively insensitive to the molecular weight.
If there is no literature value for the diffusion coefficient, it may determined experimentally, e.g. by analytical ultracentrifugation or light scattering. Alternatively, the diffusion coefficient may be estimated from the molecular and the shape factor, or frictional rate, according to the equation
1
342.3 X -—— x lO-11 (12)
M x f χ η ret
where D is the diffusion coefficient (m2/s), M is the molecular weight (daltons), f is the frictional ratio, and ηΓει is the viscosity of the solvent relative to water at 20° C.
From equations (9) and (10), the mass transport coefficient km can thus be calculated. For Biacore® systems, a Biacore-specific mass transfer constant kt may be obtained by adjusting for the molecular weight of the analyte and conversion from measured response (in RU) to concentration units:
kt= km x M x \09 (13)
where the conversion constant 109 is approximate and only valid for protein analytes and a specific sensor surface, Sensor Chip CM5 (GE Healthcare, Uppsala, Sweden) . For other analytes / sensor surfaces a calibration of the system with a RU conversion factor is required (1 RU equals x ng/mm2).
For evaluation of calibration-free concentration measurements, using the
relationship between the diffusion properties of the analyte together with analysisi of the binding rate under partially diffusion-controlled conditions, the mass transport coefficient is calculated from the diffusion coefficient, and then converted to the mass transport constant kt which is used in fitting the experimental data to the diffusion-controlled interaction model whereby the analyte concentration of the sample can be obtained.
More particularly, in calibration-free concentration assays (CFCA), a liquid sample containing the analyte, e.g. a protein, is run at several flow rates against an immobilized ligand, the initial binding rate (dR/dt) of each run being determined, in the case of a Biacore® system using SPR detection technology. The analyte concentration C is then evaluated, typically by dedicated software, by fitting the binding data to a model with a global variable for the analyte concentration. That is, setting the analyte concentration as a parameter to fit and km as a known constant together with the molecular weight Mw, so that the model is constrained to find a single concentration value that best fits all binding curves simultaneously.
Usually, it is sufficient to use only two flow rates, provided that they are widely separated, preferably as widely separated as the system used will allow.
Thus, the current implementation of the technology in Biacore® systems involves two binding experiments where analyte binds to immobilized ligand; one experiment at a low flow rate (often 5 or 10 μΐ/min) and one experiment at a high flow rate (often 100 μΐ/min). In the analysis, responses are checked for transport (diffusion) limited behavior and the response is fitted to a kinetic model where the transport coefficient is constant and the concentration of the analyte is fitted. (For details it is referred to 28-9768-788A Biacore T200 Software Handbook [GE Healthcare,
Uppsala, Sweden], the relevant disclosure of which is incorporated by reference herein).
Generally, binding rates should be measured shortly after start of the sample injection, since the rates approach zero as the binding approaches a steady state. Calibration-free assays are usually set up a direct binding format in order to obtain the high binding capacities that are usually required.
The invention
In typical CFCA experiments, several dilutions of the sample are analysed and evaluated separately. According to the present invention, a more robust analysis and one which has an extended dynamic range is obtained by including several (e.g. at least three) or all dilutions in a global fit of concentration data, so that the same fitting criteria are applied to several dilutions of the sample. This will also facilitate sensitivity analysis of the results as it becomes possible to determine whether other concentration values can be used to obtain identical or similar quality of global analysis.
As an illustration of how the method of the invention may be performed with
Biacore® system, the scripting language used in the dedicated Biaevaluation software may, for example, be as follows: The total response comes from complex formation and from refractive index change AB+$1*RI.
Short expressions define:
$1 - When injection takes place $1 expression is equal to one during injection between tonl and toffl otherwise zero.
$ 1 = (sign(t-ton 1 ) -sign(t-toff 1 )) / 2 ;
S2 describes the transport of analyte to the sensor surface, kt corresponds to the transport coefficient at one μΐ/min. Fl is the flow rate. Cone is the stock
concentration of the sample. Dil is the dilution factor that gives the concentration in the actual sample. A is the cone of analyte at the sensor surface.
$2=FlA(l/3)*kt*(Conc/Dil*$l-A); $3 is just the rate equation.
$3=ka*A*B-kd*AB;
A describes how the the analyte concentration varies over time. The starting value is zero.
A=$2-$3 I 0;
B describes how the ligand concentration changes over time. The starting value is Rmax.
B=-$3 I Rmax;
AB is how the complex is formed.
AB=$3 I 0; kt, Fl , Dil, tonl, toffl are constants;
ka, kd, Rmax are fitted globally (Rmax can be locally/ globally fitted to subgroups when several ligand densities are used);
C is fitted globally.
With "global data" it becomes possible to perform sensitivity analysis of the fit. This can be similar to U value analysis in kinetic analysis. This may, for instance be done by taking the Cone value determined, say, 100 nM, then refitting the data with changed Cone that is input as a constant, for instance 80 nM, and refitting the data using the same floating parameters as before. A computer routine may display overlay plots, residuals or chi 2 and highlight when a significant change has taken place.
In a similar way CFCA in single cycle mode is:
AB+offset*$2;
$ 1 = (sign(t-ton 1 ) -sign(t-tonoff)) / 2 ;
$2=(sign(t- tonoff)-sign(t-toff2)) /2;
$3=ktl*$l*(Conc-A)+kt2*$2*(Conc-A);
$4=ka*A*B-kd*AB;
A=$3-$4 I 0;
B=-$4 | Rmax;
AB=$410
While in the method of the invention sample injections may be made for each different flow rate, the need to inject samples in two or more cycles may be overcome by the "single cycle" approach described above, where the flow rate varies during one sample injection. For instance, the sample may be injected at 10 μΐ/min, and after 5-20 seconds the flow rate is increased to 100 μΐ/min. In the data analysis, this is handled by input of actual flow rates in the evaluation algorithms used.
The method of the invention may, optionally, be combined with a newly developed calibration-free concentration analysis method where sensor surfaces or surface areas with varying ligand density (i.e. an array of different ligand densities) are used and a fitting algorithm for determining the maximum initial binding rate and thereby the active concentration is provided.
This method, which is described in our co-pending application "Method of determining active concentration" filed on even date with the present application (the disclosure of which is incorporated by reference herein), is based on using the following equation which applies for a reaction that is totally limited by the transport efficiency of the system:
dR
T, = (14>
where R is the detector response, km is the mass transport coefficient, and C is the analyte concentration of the sample. That is, the response increase dR/dt, or binding rate, at the sensor surface is proportional to the mass transport coefficient and the active concentration of the analyte. From equation (14) it is seen that if the (initial) binding rate dR/dt at total transport limitation and km are known, the analyte concentration C may be calculated by dividing dR/dt by km.
More specifically, in that method, initial binding rates are measured at a number of (preferably at least four) different ligand density levels, i.e. immobilization levels. For each immobilization level, the response is recorded using at least one fixed flow rate. The initial binding rate is plotted versus the immobilization level, or maximal binding capacity Rmax, and the binding rate where dR/dt has reached its maximum is determined by extrapolation of the data, typically using an algorithm capable thereof. This maximum binding rate corresponds to the binding rate at mass transport limitation, meaning that equation (14) above applies, and the active concentration C can therefore be calculated by dividing dR/dt by km.
Such combined analysis will thus take into account both analysis under partial transport limitation (according to the method of the present invention) and extrapolation to complete transport limitation (as outlined above) and therefore has the potential to become more robust.
The contacting of the sample with surfaces or surface areas with different ligand densities may be performed in an analytical instrument having a single sensor surface by sequential sample injections and varying the ligand density between injections. Preferably, however, the method is performed with a multi-flow channel instrument, such as the Biacore™ T100, T200 or 4000 (GE Healthcare, Uppsala, Sweden) or ProteOn™ XPR system (Bio-Rad Laboratories, Hercules, CA, USA), preferably by parallel sample injections. In an advantageous method of determining active concentration in a calibration-free format, (initial) binding rate data are collected at different immobilization levels and at different flow rates at partial or complete transport limitation for a number of different sample dilutions. One then has the choice to evaluate the obtained binding rate data according to several alternatives, i.e. either by (i) analysis under partial transport limitation with global fitting of data for several dilutions of a sample; or (ii) extrapolation to complete transport limitation; or (iii) a combination of (i) and (ii).
The invention will now be illustrated further by means of the following non-limiting examples.
EXAMPLES
Example 1
Global fit of CFCA data
A procedure for determining active concentration by the method of the present invention using, for example, a modified Biacore® T200 system may be performed as follows. The experiments described here demonstrate antibody binding to an immobilized protein A derivative capable of binding antibody. The conventional CFCA analysis is illustrated in Fig. 1.
The analyte was injected in separate cycles at varying flow rates. In this case the analyte was diluted 400 times relative to its stock concentration. CFCA analysis gives the local antibody concentration as 19.1 nM and thus the stock solution is 7.6μΜ.
In many cases, however, it is useful to test several dilutions of the sample and analysis becomes tedious. By turning to a global fit of the data several
concentrations are analysed at the same time, as shown in Fig. 2.
This graph illustrates the global fit of antibody dilutions 1:400, 1 : 1200, 1 :3600 and 1: 10800. Each dilution is injected at two flow rates and the globally determined concentration for the stock solution is 7.6 μΜ. This immediately demonstrates that the concentration analysis is not dilution dependent and simplifies the analysis.
The present invention is not limited to the above-described preferred embodiments. Various alternatives, modifications and equivalents may be used. Therefore, the above embodiments should not be taken as limiting the scope of the invention, which is defined by the appending claims.

Claims

Claims
1. A method of determining active concentration of an analyte in a liquid sample, comprising the steps of:
(a) contacting a laminar flow of the sample with a solid phase surface or surface area supporting a ligand capable of specifically binding the analyte at at least two different flow rates and under partially or completely mass transport limited conditions;
(b) determining the initial binding rate dR/dt of analyte to the ligand at the ligand-supporting surface or surface area, and
(c) fitting the initial binding rate data obtained in step (b) to a kinetic interaction model that includes a term for mass transport to obtain the active analyte concentration,
wherein steps (a) and (b) are performed at a plurality of different dilutions of the liquid sample, and
wherein in step (c) at least several of the plurality of dilutions of the liquid sample are in included in a global fit of initial binding rate data to the kinetic interaction model.
2. The method according to claim 1 , wherein the method is performed at two substantially different flow rates.
3. The method according to claim 1 or 2, wherein the different flow rates are obtained by varying the flow rate during a single contacting cycle.
4. The method according to claim 1 , 2 or 3, wherein at least three, and preferably at least five different sample dilutions are used.
5. The method according to any one of claims 1 to 4, which further comprises contacting a laminar flow of the liquid sample with a plurality of solid phase surfaces or surface areas, each surface or surface area having a different ligand density, determining from the initial binding rates the initial binding rate corresponding to transport-limited interaction at the surfaces or surface areas, and from that binding rate determining the active analyte concentration.
6. The method according to any one of claims 1 to 5, wherein an interaction analysis sensor is used, preferably a biosensor.
7. The method according to claim 6, wherein the interaction analysis sensor is based on mass-sensing, preferably evanescent wave sensing, especially surface plasm on resonance (SPR).
8. The method according to any one of claims 1 to 7, which is computer- implemented.
9. A computer program product comprising instructions for causing a computer to perform the method steps of any one of claims 1 to 7.
PCT/SE2012/050717 2011-06-30 2012-06-27 Method of determining active concentration by calibration-free analysis Ceased WO2013002717A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CN201280032274.8A CN103620410B (en) 2011-06-30 2012-06-27 By exempting from the method that correction analysis method determines active concentration
US14/130,009 US20140141529A1 (en) 2011-06-30 2012-06-27 Method of determining active concentration by calibration-free analysis
JP2014518495A JP5855246B2 (en) 2011-06-30 2012-06-27 Determination of active concentration by calibration-free analysis
EP12805115.8A EP2726876B1 (en) 2011-06-30 2012-06-27 Method of determining active concentration by calibration-free analysis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE1150612-8 2011-06-30
SE1150612 2011-06-30

Publications (1)

Publication Number Publication Date
WO2013002717A1 true WO2013002717A1 (en) 2013-01-03

Family

ID=47424390

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE2012/050717 Ceased WO2013002717A1 (en) 2011-06-30 2012-06-27 Method of determining active concentration by calibration-free analysis

Country Status (5)

Country Link
US (1) US20140141529A1 (en)
EP (1) EP2726876B1 (en)
JP (1) JP5855246B2 (en)
CN (1) CN103620410B (en)
WO (1) WO2013002717A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015197500A1 (en) * 2014-06-24 2015-12-30 Ge Healthcare Bio-Sciences Ab Normalization of mass transport properties on optical sensor surfaces
WO2017168083A1 (en) 2016-03-29 2017-10-05 Universite de Bordeaux Method for determining active concentrations and/or kinetic interaction constants in complex biological samples by means of surface plasmon resonance
WO2020234617A1 (en) * 2019-05-22 2020-11-26 Biomerieux Methods and systems for manufacturing a production assay reactor

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3115768B1 (en) * 2015-07-07 2017-12-27 Malvern Instruments Limited Method and apparatus for determining diffusion properties of a sample
GB201516992D0 (en) * 2015-09-25 2015-11-11 Ge Healthcare Bio Sciences Ab Method and system for evaluation of an interaction between an analyte and a ligand using a biosensor
GB201517985D0 (en) * 2015-10-12 2015-11-25 Ge Healthcare Bio Sciences Ab A method in a surface plasmon resonance biosensor system
GB201705280D0 (en) 2017-03-31 2017-05-17 Ge Healthcare Bio Sciences Ab Methods for preparing a dilution series
GB201720162D0 (en) * 2017-12-04 2018-01-17 Univ Oxford Innovation Ltd Method
JP6613421B2 (en) * 2018-04-20 2019-12-04 株式会社Isa lift device
EP3792616A4 (en) * 2018-05-09 2022-01-19 Shanghai Jiao Tong University SOLID PHASE SURFACE AND SOLUTION MOTION MODE AND MOTION DEVICE
WO2020234691A1 (en) * 2019-05-17 2020-11-26 Creoptix Ag Methods for determining kinetic parameters of a reaction between analyte and ligands
CN119470342A (en) * 2024-10-17 2025-02-18 中山大学 A method for accelerating analyte detection

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004109284A1 (en) * 2003-06-06 2004-12-16 Biacore Ab Method and system for determination of molecular interaction parameters
WO2009025680A1 (en) * 2007-08-20 2009-02-26 Nomadics, Inc. Gradient injection for biosensing
WO2011049530A1 (en) * 2009-10-23 2011-04-28 Ge Healthcare Bio-Sciences Ab Method for determination of macromolecular multimers

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1631829B1 (en) * 2003-06-06 2016-04-13 GE Healthcare Bio-Sciences AB Method and apparatus for characterization of interactions
SE0302525D0 (en) * 2003-09-24 2003-09-24 Biacore Ab Method and system for interaction analysis
WO2005063815A2 (en) * 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Fcϝ receptor-binding polypeptide variants and methods related thereto
CN101583872A (en) * 2006-09-14 2009-11-18 通用电气健康护理生物科学股份公司 A method of determining analyte concentration

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004109284A1 (en) * 2003-06-06 2004-12-16 Biacore Ab Method and system for determination of molecular interaction parameters
WO2009025680A1 (en) * 2007-08-20 2009-02-26 Nomadics, Inc. Gradient injection for biosensing
WO2011049530A1 (en) * 2009-10-23 2011-04-28 Ge Healthcare Bio-Sciences Ab Method for determination of macromolecular multimers

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KARLSSON R. ET AL.: "Analysis of active antibody concentrations. Separation of affinity and concentration parameters", JOURNAL OF IMMUNOLOGICAL METHODS, vol. 166, 1993, pages 75 - 84, XP023656786 *
KAZEMIER B. ET AL.: "Determination of active single chain antibody concentration in crude periplasmic fractions", JOURNAL OF IMMUNOLOGICAL METHODS, vol. 194, no. 2, 1996, pages 201 - 209, XP004021244 *
SIGMUNDSSON K. ET AL.: "Determination of active concentration and association and dissociation rate constants of interacting biomolecules: an analytical solution to the theory for kinetic and mass transport limitations in biosensor technology ant its experimental verifications", BIOCHEMISTRY, vol. 41, 2002, pages 8263 - 8276, XP008155383 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015197500A1 (en) * 2014-06-24 2015-12-30 Ge Healthcare Bio-Sciences Ab Normalization of mass transport properties on optical sensor surfaces
JP2017519216A (en) * 2014-06-24 2017-07-13 ジーイー・ヘルスケア・バイオサイエンス・アクチボラグ Normalization of mass transfer characteristics on the surface of an optical sensor
US11047859B2 (en) 2014-06-24 2021-06-29 Cytiva Sweden Ab Normalization of mass transport properties on optical sensor surfaces
WO2017168083A1 (en) 2016-03-29 2017-10-05 Universite de Bordeaux Method for determining active concentrations and/or kinetic interaction constants in complex biological samples by means of surface plasmon resonance
WO2020234617A1 (en) * 2019-05-22 2020-11-26 Biomerieux Methods and systems for manufacturing a production assay reactor

Also Published As

Publication number Publication date
EP2726876B1 (en) 2017-10-11
CN103620410A (en) 2014-03-05
EP2726876A1 (en) 2014-05-07
JP5855246B2 (en) 2016-02-09
EP2726876A4 (en) 2015-03-11
JP2014521062A (en) 2014-08-25
CN103620410B (en) 2016-07-13
US20140141529A1 (en) 2014-05-22

Similar Documents

Publication Publication Date Title
EP2726876B1 (en) Method of determining active concentration by calibration-free analysis
Schasfoort Introduction to surface plasmon resonance
US11796536B2 (en) Method for determining analyte-ligand binding on a sensor surface
CN102667448B (en) Method and system for interaction analysis
JP2017504805A (en) Method and system for interaction analysis
CN102667447B (en) Method and system for combined behavioral analysis
US20140147937A1 (en) Method of determining active concentration
WO2006135309A9 (en) Method and system for affinity analysis
US20070016378A1 (en) Method and system for affinity analysis
US10658072B2 (en) Method and system for interaction analysis
EP2553457B1 (en) Method for determination of binding stoichiometry
US20110152120A1 (en) method of characterizing antibodies

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12805115

Country of ref document: EP

Kind code of ref document: A1

REEP Request for entry into the european phase

Ref document number: 2012805115

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2012805115

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2014518495

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 14130009

Country of ref document: US